The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed May 24, 2021. Its latest SEC filing is a REVOKED from Nov 16, 2023.
10-Q for Q3 FY2021, filed May 24, 2021
The sections below describe the company as of the FY2020 annual report.
Sells medical devices, including needle-destruction devices, thermometers and protective equipment, to healthcare providers, schools and law-enforcement agencies; also markets branded generic drugs and leases commercial property.
10-K for FY2020, filed Nov 18, 2020Currently, we are a diversified holding company which, through our subsidiaries, is engaged in sales and distribution of medical devices…View ↗
Through our medical products business unit, we manufacture and sell our Sharps and Needle Destruction Devices (SANDD mini™, SANDD Pro™…View ↗
Our real estate leasing revenues are generated from a commercial and residential property under a long-term lease. Additionally, our real…View ↗
Needle Destruction Devices. The SANDD™ needle incineration units are FDA cleared and Occupational Safety and Health Administration (“OSHA”)…View ↗
Personal Protection Equipment. We offer for sale a line of face masks and face shields including a Level 1 single use disposable mask, a…View ↗
Additionally, during the year ended June 30, 2020, we launched the sale of our needle destruction device (SANND mini™) into the Texas…View ↗
Medical devices and branded generics are marketed to healthcare providers, public institutions and emergency-service users. UK health commissioning groups buy branded generics through Alliance Healthcare; medical products are also handled through third-party distributors and sales representatives.
10-K for FY2020, filed Nov 18, 2020We have sold our branded generic drugs to approximately five of the approximately 225 CCG’s through an exclusive distribution agreement…View ↗
Our medical devices and branded generics are to be marketed to a broad base of users, and we believe they are ideal for home and…View ↗
We have distributorship and sales representative agreements in place with third parties who do not take ownership of products. Any costs…View ↗
10-Q for Q3 FY2021, filed May 24, 2021
−$445.6KView ↗
8-K, filed May 11, 2023
On May 1, 2023, RedHawk Medical was awarded a monetary judgment (“Judgment”) in the amount of $44,950,000, plus, attorney fees and…View ↗
8-K, filed May 11, 2022
Year Ending Year Ended June 30, June 30, 2022 2021 2020 (Forecast) (Unaudited) (Audited) Revenues under contract from the sale of medical…View ↗
8-K, filed Apr 1, 2022
The Registrant announced today that it agreed to now offer for sale vacuum blood collection tubes (“VBCT”).View ↗
Expanded needle-device line
The older report describes SANDD mini as the needle-destruction product; the latest report also says it is accepting orders for SANDD Pro and SANDD Pro Portable.
10-K for FY2017, filed Nov 1, 2017 10-K for FY2020, filed Nov 18, 2020The proper management of medical waste, also referred to as biohazardous waste, biomedical waste or infectious waste, which is generated in…View ↗
On September 22, 2018, RedHawk Medical Products, LLC, a wholly owned subsidiary of the Company, entered an agreement to acquire the…View ↗
Added protective equipment
Medical sales broadened to include protective equipment, with masks, face shields and sanitation lights offered.
10-K for FY2017, filed Nov 1, 2017 10-K for FY2020, filed Nov 18, 2020The Company, through its medical products business unit, we manufacture and sell our Sharps and Needle Destruction Device (SANDD mini™) and…View ↗
Loading...
